A new path to platelet production through matrix sensing
EHA Learning Center, Vittorio Abbonante, 190341
The endothelin B receptor plays a crucial role in the adhesion of neutrophils to the endothelium in sickle cell disease
EHA Learning Center, Bérengère Koehl, 190342
Imatinib and spironolactone suppress hepcidin expression
EHA Learning Center, Katarzyna Mleczko-Sanecka, 190343
Venous thromboembolism is associated with graft-versus-host disease and increased non-relapse mortality after allogeneic hematopoietic stem cell transplantation
EHA Learning Center, Natasha Kekre, 190344
Bleeding risk of surgery and its prevention in patients with inherited platelet disorders
EHA Learning Center, Sara Orsini, 190345
Epigenetically induced ectopic expression of UNCX impairs the proliferation and differentiation of myeloid cells
EHA Learning Center, Giulia Daniele, 190346
A three-dimensional ex vivo tri-culture model mimics cell-cell interactions between acute myeloid leukemia and the vascular niche
EHA Learning Center, Laura J. Bray, 190347
Precision and prognostic value of clone-specific minimal residual disease in acute myeloid leukemia
EHA Learning Center, Pierre Hirsch, 190348
Development of a modified prognostic index for patients with aggressive adult T-cell leukemia-lymphoma aged 70 years or younger: possible risk-adapted management strategies including allogeneic transplantation
EHA Learning Center, Shigeo Fuji, 190351
Monitoring multiple myeloma by quantification of recurrent mutations in serum
EHA Learning Center, Even Rustad, 190352
Resistin induces multidrug resistance in myeloma by inhibiting cell death and upregulating ABC transporter expression
EHA Learning Center, Jianan Pang, 190353
Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wide copy number array analysis
EHA Learning Center, Martin Granzow, 190354
Effect of antithymocyte globulin source on outcomes of bone marrow transplantation for severe aplastic anemia
EHA Learning Center, Natasha Kekre, 190355
From biology to targeted therapies in chronic lymphocytic leukemia
EHA Learning Center, Stephan Stilgenbauer, 184561
Hemophilia Treatment: Navigating Speed Bumps on the Innovation Highway
EHA Learning Center, Donna DiMichele, 184560
INDUCTION OF HEMOGENIC REPROGRAMMING IN HUMAN FIBROBLASTS
EHA Learning Center, Andreia Gomes, 183930
Managing CLL patients after BCR inhibitor failure
EHA Learning Center, Jeffrey Jones, 184553
Treatment Of Aggressive Lymphoma Focused On Elderly Patients
EHA Learning Center, Michael Pfreundschuh, 184545
New Treatment Approaches In Myeloma In 2017
EHA Learning Center, Jesus F. San Miguel, 184549
Harnessing T cells for Immunotherapy of AML
EHA Learning Center, Marion Subklewe, 184556
New drugs for old? What is the role of B-cell receptor pathway inhibition in the front line therapy of CLL in 2017?
EHA Learning Center, Stephen Devereux, 184552
CRYPTIC INSERTIONS OF IMMUNOGLOBULIN LIGHT CHAIN ENHANCER REGIONS ACTIVATE CCND3 AND CCND2 IN CYCLIN D1-NEGATIVE MANTLE CELL LYMPHOMAS
EHA Learning Center, Silvia Bea, 183929
BONE MARROW SITES DIFFERENTLY IMPRINT DORMANCY AND CHEMORESISTANCE TO T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Françoise Pflumio, 183931
ANTI-CD69 MAB TREATMENT INCREASES THE CAPACITY OF NK CELLS TO ELIMINATE HYPER-REACTIVE ALLOGENIC T CELLS AND PREVENTS ACUTE GRAFT VERSUS HOST DISEASE
EHA Learning Center, Katerina Tsilingiri, 183933
Relapsed aggressive lymphoma: Can we optimize the therapy
EHA Learning Center, Gilles Salles, 184544
Genetic Classification Of Myeloma For Prognostication And Treatment Selection
EHA Learning Center, Hervé Avet-Loiseau, 184548
First-line therapy for CLL in 2017
EHA Learning Center, Alessandra Tedeschi, 184551
Role of enhancers in the pathogenesis of AML
EHA Learning Center, Ruud Delwel, 184555
ARNT/HIF-1BETA LINKS POOR CLINICAL OUTCOME TO MICROENVIRONMENTAL HYPOXIA AND HIGH-RISK 1Q GAIN IN MULTIPLE MYELOMA
EHA Learning Center, Fengyan Jin, 183932
Iron Chelation in Hemoglobinopathies 
EHA Learning Center, Vip , 192910
GLOBAL PIVOTAL PHASE 2 TRIAL OF THE CD19-TARGETED THERAPY CTL019 IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)—AN INTERIM ANALYSIS
EHA Learning Center, Gilles Salles, 183934
The Biological Basis Of Aggressive Lymphoma
EHA Learning Center, Elias Campo, 184543
Immunopathology of MM
EHA Learning Center, Nikhil Munshi, 184547
GvL / GvHD
EHA Learning Center, Fred Falkenburg, 192908
Pregnancy during and after treatment. Myths and reality.
EHA Learning Center, Jane Apperley, 192902
Prioritisation Therapies In CLL
EHA Learning Center, Clemens Wendtner, 184524
Indications For Transplantation In MDS
EHA Learning Center, Matteo Giovanni Della Porta, 184533
Red Cell Transfusion: When To Transfuse In Patients With Hematological Malignancies?
EHA Learning Center, Miguel Lozano Molero, 184537
Heat Shock Protein 70 (HSP70), one of the major key factors in Diamond-Blackfan anemia
EHA Learning Center, Lydie Da Costa, 184541
ELN-EHA-SWG on CML
EHA Learning Center, Jerry Radich, 184529
Prognostic Factors In CLL: When, Which And How?
EHA Learning Center, Sarka Pospisilova, 184523
ELN-EHA-SWG on CML
EHA Learning Center, Daniela Krause, 184528
Immune microenvironment in the pathogenesis of MDS
EHA Learning Center, Shahram Kordasti, 184532
Challenges In Typing And Matching Strategies In Patients With Hematological Maligancies In The Era Of Immunotherapy
EHA Learning Center, Karen Vooght, 184536
Iron overload before, during and after bone marrow transplantation
EHA Learning Center, Emanuele Angelucci, 184539
ELN-EHA-SWG on CML
EHA Learning Center, Alois Gratwohl, 184527
Relevance Of Microenvironment In CLL
EHA Learning Center, Federico Caligaris-Cappio, 184522
ELN-EHA-SWG on CML
EHA Learning Center, Delphine Rea, 184526
Clonal Evolution In MDS
EHA Learning Center, Joop Jansen, 184531
Cell-derived Microvesicles And Microparticles In Blood Components: Consequences For Transfusion Recipients
EHA Learning Center, Thierry Burnouf, 184535
Transferrin and TfR1 in co-regulation of erythropoiesis and iron metabolism
EHA Learning Center, Yelena Ginzburg, 184540
THE DUAL SYK/JAK INHIBITOR CERDULATINIB DEMONSTRATES COMPLETE INHIBITION OF SYK AND JAK AND RAPID TUMOR RESPONSES IN A PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES
EHA Learning Center, Paul Hamlin, 182060
13-YR FOLLOW UP OF MULTICENTER RANDOMIZED CHOP-R VS R-HDS TRIAL IN HIGH RISK FOLLICULAR LYMPHOMA PATIENTS: PROLONGED SURVIVAL AND HIGH RATE OF LONG-TERM DISEASE FREE SURVIVORS
EHA Learning Center, Corrado Tarella, 182065
PEMBROLIZUMAB PLUS LENALIDOMIDE AND LOW-DOSE DEXAMETHASONE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EFFICACY AND BIOMARKER RESULTS FROM THE PHASE 1 KEYNOTE-023 STUDY
EHA Learning Center, Paula Rodriguez-Otero, 182070
POOLED SURVIVAL ANALYSIS OF MIDOSTAURIN CLINICAL STUDY DATA (D2201 + A2213) IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM) COMPARED WITH HISTORICAL CONTROLS
EHA Learning Center, Andreas Reiter, 182075
A PHASE 1B STUDY OF THE COMBINATION OF VADASTUXIMAB TALIRINE AND 7+3 INDUCTION THERAPY FOR PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML)
EHA Learning Center, Moshe Y. Levy, 182080
ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA WITH DELETION 5Q OR MONOSOMY 5: A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY (ALWP) OF THE EBMT
EHA Learning Center, Xavier Poiré, 182085
T-CELL RECEPTOR Β (TRB) REPERTOIRE CHARACTERISTICS IN RELAPSED/REFRACTORY (R/R) B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BCP-ALL) ON BLINATUMOMAB TREATMENT.
EHA Learning Center, Henrik Knecht, 182090
EFFICACY AND SAFETY OF DEFIBROTIDE TO TREAT HEPATIC VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) POST-CHEMOTHERAPY: A POST HOC ANALYSIS OF FINAL DATA OF AN EXPANDED-ACCESS PROTOCOL
EHA Learning Center, Stephan Grupp, 182095
DIFFERENT IRON SOURCES AND ACQUISITION PATHWAYS SHAPE MACROPHAGES TOWARDS OPPOSING FUNCTIONAL PHENOTYPES
EHA Learning Center, Francesca Vinchi, 182100
CARD9 CONTROLS DECTIN-1-INDUCED T-CELL CYTOTOXICITY AND TUMOR GROWTH IN MICE
EHA Learning Center, Tobias Haas, 182105
CHEMO-FREE TRIPLET COMBINATION OF TGR-1202, UBLITUXIMAB, AND IBRUTINIB IS WELL TOLERATED AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED CLL AND NHL
EHA Learning Center, Loretta Nastoupil, 182059
DYNAMO: A PHASE 2 STUDY DEMONSTRATING THE CLINICAL ACTIVITY OF DUVELISIB IN PATIENTS WITH DOUBLE-REFRACTORY FOLLICULAR LYMPHOMA
EHA Learning Center, Pier Luigi Zinzani, 182064
COMPARISON OF DENOSUMAB (DMB) WITH ZOLEDRONIC ACID (ZA) FOR THE TREATMENT OF BONE DISEASE IN PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; AN INTERNATIONAL, RANDOMIZED, DOUBLE BLIND TRIAL
EHA Learning Center, Evangelos Terpos, 182069
MOLECULAR RESPONSE TO HYDROXYUREA AND ROPEGINTERFERON ALFA-2B IN THE PROUD-PV RANDOMIZED PHASE 3 TRIAL
EHA Learning Center, Jean-Jacques Kiladjian, 182074
SORAFENIB MAINTENANCE IN FLT3-ITD MUTATED ACUTE MYELOID LEUKEMIA AFTER ALLOGENEIC STEM CELL TRANSPLANT
EHA Learning Center, Betül Oran, 182079
CYCLOPHOSPHAMIDE VERSUS ETOPOSIDE IN COMBINATION WITH TOTAL BODY IRRADIATION AS CONDITIONING FOR ADULTS WITH PH(-) ALL UNDERGOING ALLO-HCT. A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT
EHA Learning Center, Sebastian Giebel, 182084
POST-INDUCTION MRD PREDICTS HIGH RELAPSE RISK FOLLOWING REDUCED INTENSITY CONDITIONED ALLOGENEIC STEM CELL TRANSPLANTATION: A PROSPECTIVE STUDY OF ADULT ALL (UKALL14,ISRCTN 66541317)
EHA Learning Center, Dina Okasha, 182089
LETERMOVIR (LET) FOR PREVENTION OF CYTOMEGALOVIRUS (CMV) INFECTION IN ADULT CMV-SEROPOSITIVE RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT)
EHA Learning Center, Rafael Duarte, 182094
INTRAVENOUS IRON VERSUS ORAL IRON VERSUS NO IRON WITH OR WITHOUT ERYTHROPOIESISSTIMULATING AGENTS (ESA) FOR CANCER PATIENTS WITH ANAEMIA: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
EHA Learning Center, Aaron Weigl, 182099
MESENCHYMAL STROMAL CELLS FOR THE TREATMENT OF STEROID-RESISTANT ACUTE GRAFT VERSUS HOST DISEASE: FACTORS INFLUENCING CLINICAL RESPONSES
EHA Learning Center, Antonio Galleu, 182104
VENETOCLAX IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION: OUTCOME AND MINIMAL RESIDUAL DISEASE FROM THE FULL POPULATION OF THE PIVOTAL M13-982 TRIAL
EHA Learning Center, Stephan Stilgenbauer, 182058
EFFICACY AND SAFETY OF COPANLISIB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: A SUBSET ANALYSIS OF THE CHRONOS-1 STUDY
EHA Learning Center, Pier Luigi Zinzani, 182063
LENALIDOMIDE INDUCTION AND MAINTENANCE THERAPY FOR TRANSPLANT ELIGIBLE MYELOMA PATIENTS: RESULTS OF THE MYELOMA XI STUDY
EHA Learning Center, Charlotte Pawlyn, 182068
PHASE 3 RANDOMIZED TRIAL OF MOMELOTINIB VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH MYELOFIBROSIS PREVIOUSLY TREATED WITH RUXOLITINIB: RESULTS OF THE SIMPLIFY-2 STUDY
EHA Learning Center, C Harrison, 182073
MOLECULAR PREDICTORS OF RESPONSE TO AZACITIDINE THERAPY: THE RESULTS OF THE UK TRIALS ACCELERATION PROGRAMME RAVVA STUDY
EHA Learning Center, Charles Craddock, 182078
IMPACT OF HLA DISPARITY ON OUTCOME IN HLA-HAPLOIDENTICAL BONE MARROW TRANSPLANTATION FOLLOWED BY HIGH DOSE POST-TRANSPLANT CYCLOPHOSPHAMIDE
EHA Learning Center, Livia , 182083
MULTI-CENTER VALIDATION OF STANDARDIZED NGS ASSAYS FOR REARRANGED IG / TR MARKER DETECTION IN ACUTE LYMPHOBLASTIC LEUKEMIA - A REPORT OF THE EUROCLONALITY-NGS CONSORTIUM
EHA Learning Center, Monika Brüggemann, 182088
INFECTION-RELATED MORTALITY (IRM) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: AGE, CMV AND PRE-TRANSPLANT LEVELS OF IGA/IGM PREDICT IRM IN A NEW CLINICO-BIOLOGICAL SCORING SYSTEM
EHA Learning Center, Alessandra Forcina, 182093
UNRAVELING THE MOLECULAR PATHOGENESIS OF INEFFECTIVE ERYTHROPOIESIS IN CONGENITAL DYSERYTHROPOIETIC ANEMIA TYPE II: IN VITRO EVALUATION OF RAP-011 TREATMENT
EHA Learning Center, Gianluca De Rosa, 182098
GENERATION OF MEMORY STEM T CELLS (TSCM) MODIFIED WITH A NOVEL OPTIMIZED CD30-SPECIFIC CHIMERIC ANTIGEN RECEPTOR (CAR) FOR THE TREATMENT OF CD30+ T-CELL MALIGNANCIES
EHA Learning Center, Laura Escribà, 182103
THE INITIAL REPORT OF THE BLOODWISE TAP CLARITY STUDY COMBINING IBRUTINIB AND VENETOCLAX IN RELAPSED, REFRACTORY CLL SHOWS ACCEPTABLE SAFETY AND PROMISING EARLY INDICATIONS OF EFFICACY
EHA Learning Center, Peter Hillmen, 182057
IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (FL) IN THE RANDOMIZED PHASE III GALLIUM STUDY: ANALYSIS BY CHEMOTHERAPY REGIMEN
EHA Learning Center, Wolfgang Hiddemann, 182062
TWICE-WEEKLY IXAZOMIB PLUS LENALIDOMIDE-DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: LONG-TERM FOLLOW-UP DATA FOR PATIENTS WHO DID NOT UNDERGO STEM CELL TRANSPLANTATION (SCT)
EHA Learning Center, Paul Richardson, 182067
PHASE 3 RANDOMIZED TRIAL OF MOMELOTINIB VERSUS RUXOLITINIB IN JAK INHIBITOR NAIVE PATIENTS WITH MYELOFIBROSIS: RESULTS OF THE SIMPLIFY-1 STUDY
EHA Learning Center, Jason R. Gotlib, 182072
FINAL RESULTS OF THE CETLAM LAM-2003 TRIAL FOR THE TREATMENT OF PRIMARY AML UP TO THE AGE OF 70
EHA Learning Center, Ana Garrido, 182077
GUT COLONIZATION BY MULTI-DRUG RESISTANT BACTERIA IS AN INDEPENDENT RISK FACTOR FOR DEVELOPMENT OF INTESTINAL ACUTE GRAFT-VERSUS-HOST DISEASE
EHA Learning Center, Zinaida Peric, 182082
PROGNOSTIC IMPACT OF ADDITIONAL MOLECULAR LESIONS IN PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
EHA Learning Center, Anna Lucia Fedullo, 182087
CONJUGATED PNEUMOCOCCAL VACCINE TRIGGERS A BETTER IMMUNE RESPONSE THAN POLYSACCHARIDE PNEUMOCOCCAL VACCINE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIAA RANDOMIZED STUDY BY THE SWEDISH CLL GROUP
EHA Learning Center, Tobias Svensson, 182092
IDENTIFICATION OF GUANOSINE 5ʹ-DIPHOSPHATE AS POTENTIAL IRON MOBILIZER: PREVENTING THE HEPCIDIN-FERROPORTIN INTERACTION AND MODULATING THE INTERLEUKIN-6/STAT-3 PATHWAY
EHA Learning Center, Stanzin angmo, 182097
CIS IS A POTENT CHECKPOINT IN NK CELL ANTI-LEUKEMIA IMMUNITY
EHA Learning Center, Nicholas HUNTINGTON, 182102
IBRUTINIB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA: UPDATED EFFICACY AND SAFETY OF THE RESONATE STUDY WITH UP TO FOUR YEARS OF FOLLOW-UP
EHA Learning Center, Carolina Moreno Atanasio, 182056
PHASE II TRIAL OF COMBINATION OF ELOTUZUMAB, LENALIDOMIDE, AND DEXAMETHASONE IN HIGH-RISK SMOLDERING MULTIPLE MYELOMA
EHA Learning Center, Irene Ghobrial, 182066
RUXOLITINIB FOR THE TREATMENT OF INADEQUATELY CONTROLLED POLYCYTHEMIA VERA WITHOUT SPLENOMEGALY: 80-WEEK FOLLOW-UP FROM THE RESPONSE-2 TRIAL
EHA Learning Center, Martin Greisshammer, 182071
LOW-DOSE CYTARABINE TREATMENT IN CHILDREN WITH DOWN SYNDROME AND TRANSIENT MYELOPROLIFERATIVE DISORDER TO PREVENT ML-DS: AML-BFM TMD PREVENTION 2007 STUDY
EHA Learning Center, Marius Flasinski, 182076
21-COLOR FLOW CYTOMETRY REVEALS IMMUNOPHENOTYPES ASSOCIATED WITH RESPONSE IN ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) PATIENTS TREATED WITH THE JANUS KINASE (JAK) INHIBITOR INCB039110 (ITACITINIB)
EHA Learning Center, Karl Staser, 182081
IDENTIFICATIONS OF NOVEL RECURRENT PU.1 FUSIONS WITH HIGHLY AGGRESSIVE PHENOTYPE IN PEDIATRIC T CELL ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Masafumi Seki, 182086
DISCONTINUING ANTIBACTERIAL THERAPY AFTER APYREXIA AND CLINICAL STABILITY REGARDLESS OF NEUTROPHIL COUNT IN FEBRIL NEUTROPENIA IS SAFE AND REDUCES EXPOSITION TO ANTIBIOTICS (HOWLONG RANDOMIZED TRIAL)
EHA Learning Center, Ildefonso Espigado, 182091
LACK OF THE FERROPTOSIS INHIBITOR GPX4 IN ERYTHROID CELLS CAUSES A BLOCK IN RETICULOCYTE MATURATION AND A HYPOXIC SIGNATURE WITH IMPAIRED HEPCIDIN REGULATION.
EHA Learning Center, Sandro Altamura, 182096
A PHASE 3 STUDY TO EVALUATE SAFETY AND EFFICACY OF LENTIGLOBIN GENE THERAPY FOR TRANSFUSION-DEPENDENT Β-THALASSEMIA IN PATIENTS WITH NON-Β0/Β0 GENOTYPES: THE NORTHSTAR-2 (HGB-207) TRIAL
EHA Learning Center, Mark Walters, 182101